Abbott On Track To Reach U.S. Drug-Eluting Stent Market By Late 2007
This article was originally published in The Pink Sheet Daily
Executive SummaryCompany earns FDA green light for planned 1,670-patient ZOMAXX II randomized trial of ZoMaxx drug-eluting stent. Study will compare ABT-578-eluting TriMaxx-platform stent to Boston Scientific's Taxus.
You may also be interested in...
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.
Koa Accel CEO Francis Duhay outlines his company’s plans to take some of the risk out of investing in medical device start-ups by supporting inventors with functional expertise. The Irvine, CA-based medical device accelerator is focused on start-ups that will either “fail fast” or earn a 510(k) clearance within 18 months.